<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6863932\results\search\disease\results.xml">
  <result pre="permitted which does not comply with these terms. Abstract Current" exact="influenza" post="vaccines manufactured using eggs have considerable limitations, both in"/>
  <result pre="emerging pandemic strain. Here we explore the production of recombinant" exact="influenza" post="haemagglutinin using the ciliated protozoan Tetrahymena thermophila. For the"/>
  <result pre="time we were able to produce haemagglutinin from both seasonal" exact="influenza" post="A and B strains. This ciliate derived material was"/>
  <result pre="with ciliate derived haemagglutinin were protected against challenge with homologous" exact="influenza" post="A or B viruses. The antigen could also be"/>
  <result pre="economic burden worldwide (1). The World Health Organization (WHO) estimates" exact="influenza" post="epidemics to result in about 3 to 5 million"/>
  <result pre="globally each year, leading to 290,000 to 650,000 deaths. Annual" exact="influenza" post="vaccination is considered by the WHO to be the"/>
  <result pre="the most effective strategy to prevent disease caused by the" exact="influenza" post="A and B viruses currently co-circulating in humans. Vaccination"/>
  <result pre="vaccines are produced using embryonated chicken eggs (3). However, egg-based" exact="influenza" post="vaccine production is complex to scale up and work"/>
  <result pre="a limited supply of embryonated eggs due to effects of" exact="influenza" post="virus on poultry (7). Alternative approaches that can generate"/>
  <result pre="has been on cell culture-based technologies for mass production of" exact="influenza" post="vaccines and there is a licensed cell culture-based vaccine:"/>
  <result pre="of age and older (9). Completely cell cultured virus in" exact="influenza" post="vaccines, which was not propagated in eggs, can avoid"/>
  <result pre="propagated in eggs, can avoid the egg-adaptation changes of the" exact="influenza" post="virus (10). But cell lines can induce mutations, reducing"/>
  <result pre="Furthermore, cell culture-based technologies using mammalian systems for manufacturing of" exact="influenza" post="vaccine from whole virus still involve chemical virus inactivation"/>
  <result pre="is to manufacture vaccines derived from recombinant protein. For example," exact="influenza" post="antigens can be produced in insect cells using baculoviral"/>
  <result pre="antigens. However, the current market share of this approved recombinant" exact="influenza" post="antigen produced in insect cells (Flublok™ from Sanofi, Swiftwater,"/>
  <result pre="low at 1–2%. Other approaches for the production of recombinant" exact="influenza" post="antigen are being investigated, for example the expression of"/>
  <result pre="candidates for vaccines against protozoan pathogenic agents, for example the" exact="malaria" post="agent Plasmodium falciparum (18). Furthermore, it has been shown,"/>
  <result pre="also suitable as expression host for the recombinant production of" exact="influenza" post="virus proteins (19). One other consideration is post-translational modification,"/>
  <result pre="heterogeneity (16). Here we describe the production of a recombinant" exact="influenza" post="subunit vaccine by overexpression of the surface protein HA"/>
  <result pre="subunit vaccine by overexpression of the surface protein HA from" exact="influenza" post="virus A and B strains using the ciliate T."/>
  <result pre="necessary to confer immunity (3, 21), we also combined the" exact="influenza" post="antigens with PLA-Nod2 particles, a promising vaccine vehicle (22,"/>
  <result pre="HA2 including the transmembrane region and the cytoplasmic tale) of" exact="influenza" post="virus A/California/07/2009 (A/Cal; accession # EPI177294, 567 amino acids),"/>
  <result pre="were anesthetized using isoflurane and infected i.n. with 100 μl" exact="influenza" post="virus or sterile PBS. Mice were culled using 100"/>
  <result pre="a non-lethal model, to match refinement guidelines. Influenza Viruses The" exact="influenza" post="infectious viruses used for HA inhibition, virus neutralization in"/>
  <result pre="neutralization in vitro assays and in vivo challenge were seasonal" exact="influenza" post="strains obtained from NIBSC: A/California/7/2009 (H1N1, 15/252) and B/Brisbane/60/2008"/>
  <result pre="thermophila as an expression host for production of different recombinant" exact="influenza" post="HA expression vectors coding for full length HA, codon-optimized,"/>
  <result pre="immunization (Figure 2A). Both s.c. and i.m. immunization induced significant" exact="influenza" post="specific IgG already after the primary immunization, with GMT"/>
  <result pre="immunized at 3 weekly intervals with a quadrivalent mixture of" exact="influenza" post="antigens containing 45 μg each of A/NC, A/Uru, B/Jia"/>
  <result pre="were compared to 15 μg positive control egg derived inactivated" exact="influenza" post="antigen (IIV). After 3 doses of vaccine, mice immunized"/>
  <result pre="low dose of antigen had a high level of HA" exact="influenza" post="specific antibody in serum (Figure 4A). Mice were then"/>
  <result pre="1.5 μg ciliate derived A/Cal, or 15 μg control inactivated" exact="influenza" post="antigen (IIV) by the intramuscular (i.m.) route. Two weeks"/>
  <result pre="or low dose of antigen had a high level of" exact="influenza" post="B specific antibody in serum (Figure 5A). Mice were"/>
  <result pre="serum (Figure 5A). Mice were then challenged i.n. with B/Bri" exact="influenza" post="strain; there was a significant difference between vaccinated and"/>
  <result pre="post test. Discussion In the current study we show that" exact="influenza" post="HA can be produced in the ciliate T. thermophila."/>
  <result pre="antigen was immunogenic and able to protect against infection with" exact="influenza" post="A or B viruses in mice. In a small"/>
  <result pre="we show that Tetrahymena can be used to produce immunogenic" exact="influenza" post="antigens. One advantage of recombinant protein-based influenza vaccines is"/>
  <result pre="to produce immunogenic influenza antigens. One advantage of recombinant protein-based" exact="influenza" post="vaccines is the avoidance of infectious viral propagation which"/>
  <result pre="further limitation of insect cells for the production of recombinant" exact="influenza" post="vaccines is the large volume of virus needed on"/>
  <result pre="looked at comparative efficacy compared to other platforms for generating" exact="influenza" post="vaccines, and the animal models may not necessarily enable"/>
  <result pre="or interpretation. EM works for Vismederi srl, which analyses responses" exact="influenza" post="vaccines and infection, Vismederi analyzed data from the project."/>
  <result pre="https://www.frontiersin.org/articles/10.3389/fimmu.2019.02661/full#supplementary-material Figure S1 SDS-PAGE of ciliate produced, purified rHA from" exact="influenza" post="virus A and B strains. Each purified rHA was"/>
  <result pre="References References 1.SomesMPTurnerRMDwyerLJNewallAT. Estimating the annual attack rate of seasonal" exact="influenza" post="among unvaccinated individuals: a systematic review and meta-analysis. Vaccine."/>
  <result pre="changes with aging. Semin Immunol. (2018) 40:83–94. 10.1016/j.smim.2018.10.01030501873 3.TregoningJSRussellRFKinnearE. Adjuvanted" exact="influenza" post="vaccines. Human Vaccines Immunotherapeut. (2018) 14:550–64. 10.1080/21645515.2017.141568429232151 4.SubbaraoKBarrI. A"/>
  <result pre="of two mutations: beginning to understand the problems with egg-based" exact="influenza" post="vaccines?Cell Host Microbe. (2019) 25:773–5. 10.1016/j.chom.2019.05.01231194938 5.ParkerLWhartonSAMartinSRCrossKLinYLiuYet al.. Effects"/>
  <result pre="Effects of egg-adaptation on receptor-binding and antigenic properties of recent" exact="influenza" post="A (H3N2) vaccine viruses. J Gen Virol. (2016) 97:1333–44."/>
  <result pre="J Gen Virol. (2016) 97:1333–44. 10.1099/jgv.0.00045726974849 6.SkowronskiDMJanjuaNZDe SerresGSabaiducSEshaghiADickinsonJAet al.Low 2012–13" exact="influenza" post="vaccine effectiveness associated with mutation in the egg-adapted H3N2"/>
  <result pre="(2014) 9:e9215310.1371/journal.pone.009215324667168 7.PandeyASinghNSambharaSMittalSK. Egg-independent vaccine strategies for highly pathogenic H5N1" exact="influenza" post="viruses. Human Vaccines. (2010) 6:178–88. 10.4161/hv.6.2.989919875936 8.BarrIGDonisROKatzJMMcCauleyJWOdagiriTTrusheimHet al.. Cell"/>
  <result pre="viruses. Human Vaccines. (2010) 6:178–88. 10.4161/hv.6.2.989919875936 8.BarrIGDonisROKatzJMMcCauleyJWOdagiriTTrusheimHet al.. Cell culture-derived" exact="influenza" post="vaccines in the severe 2017–2018 epidemic season: a step"/>
  <result pre="in the severe 2017–2018 epidemic season: a step towards improved" exact="influenza" post="vaccine effectiveness. NPJ Vaccines. (2018) 3:44. 10.1038/s41541-018-0079-z30323955 9.IzurietaHSChillarigeYKelmanJWeiYLuYXuWet al.."/>
  <result pre="3:44. 10.1038/s41541-018-0079-z30323955 9.IzurietaHSChillarigeYKelmanJWeiYLuYXuWet al.. Relative effectiveness of cell-cultured and egg-based" exact="influenza" post="vaccines among elderly persons in the United States, 2017–2018."/>
  <result pre="characteristics of qualified cell lines for isolation and propagation of" exact="influenza" post="viruses for vaccine manufacturing. Vaccine. (2014) 32:6583–90. 10.1016/j.vaccine.2014.06.04524975811 11.LeeHKTangJWKongDHLohTPChiangDKLamTTet"/>
  <result pre="10.1016/j.vaccine.2014.06.04524975811 11.LeeHKTangJWKongDHLohTPChiangDKLamTTet al.. Comparison of mutation patterns in full-genome A/H3N2" exact="influenza" post="sequences obtained directly from clinical samples and the same"/>
  <result pre="passage. PLoS ONE. (2013) 8:e79252. 10.1371/journal.pone.007925224223916 12.SheYMChengKFarnsworthALiXCyrTD. Surface modifications of" exact="influenza" post="proteins upon virus inactivation by beta-propiolactone. Proteomics. (2013) 13:3537–47."/>
  <result pre="Appl Microbiol Biotechnol. (1999) 51:447–55. 10.1007/s00253005141510341428 18.CowanGJBockauUEleni-MuusJAldagISamuelKCreaseyAMet al.. A novel" exact="malaria" post="vaccine candidate antigen expressed in Tetrahymena thermophila. PLoS ONE."/>
  <result pre="System for the heterologous expression of NS1 protein of H9N2" exact="avian influenza" post="virus in the ciliate Tetrahymena thermophila. J Vet Med"/>
  <result pre="for the heterologous expression of NS1 protein of H9N2 avian" exact="influenza" post="virus in the ciliate Tetrahymena thermophila. J Vet Med"/>
  <result pre="induce influenza-specific CD8+ T cell responses, enabling faster resolution of" exact="influenza" post="disease. Front Immunol. (2016) 7:321. 10.3389/fimmu.2016.0032127602032 30.GrovesHTMcDonaldJULangatPKinnearEKellamPMcCauleyJet al.. Mouse"/>
  <result pre="Front Immunol. (2016) 7:321. 10.3389/fimmu.2016.0032127602032 30.GrovesHTMcDonaldJULangatPKinnearEKellamPMcCauleyJet al.. Mouse models of" exact="influenza" post="infection with circulating strains to test seasonal vaccine efficacy."/>
  <result pre="a simple and high-yielding fed-batch process for the production of" exact="influenza" post="vaccines. Vaccine. (2009) 28:309–16. 10.1016/j.vaccine.2009.10.04819879996 38.ChalmersJJ. Shear sensitivity of"/>
 </snippets>
</snippetsTree>
